Sarcoma  >>  cyclophosphamide  >>  Phase 1
Welcome,         Profile    Billing    Logout  

53 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cyclophosphamide / Generic mfg.
NCT02387125: Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Checkmark From trial for locally advanced, relapsed, or metastatic cancer at ASCO 2017
Jun 2017 - Jun 2017: From trial for locally advanced, relapsed, or metastatic cancer at ASCO 2017
Checkmark Early data from ovarian cancer
May 2017 - May 2017: Early data from ovarian cancer
Checkmark For solid tumors
More
Terminated
1b
79
US
CMB305, G100, Metronomic CPA, Cytoxan Tablets
Immune Design
Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer
03/19
03/19
NCT00001209: A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors

Completed
1
120
US
vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16
National Cancer Institute (NCI)
Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma, Sarcoma, Ewing's
 
08/00
NCT00007813: Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Completed
1
21
US
filgrastim, carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Amgen, Baxter Healthcare Corporation, Nexell Therapeutics Inc
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
02/05
02/05
NCT00003141: Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Completed
1
94
US, Canada, RoW
filgrastim, GRANULOCYTE COLONY-STIMULATING FACTOR, r-metHuG-CSF, G-CSF, carboplatin, Paraplatin, CBDCA, NSC #241240, cisplatin, Cis-diamminedichloroplatinum II, Platinol-AQ, NSC #119875, cyclophosphamide, CTX, Cytoxan, NSC #026271, etoposide, VP-16, VePesid, Etopophos, NSC #141540, thiotepa, Tespa, Tspa, NSC #639, vincristine sulfate, VCR, Oncovin, NSC #067574, conventional surgery, peripheral blood stem cell transplantation
Children's Oncology Group, National Cancer Institute (NCI)
Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
12/07
10/11
NCT00960063: A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Terminated
1
4
NA
Temozolomide, Vincristine, Ifosfamide, Irinotecan, Robatumumab, Doxorubicin, Cyclophosphamide, Etoposide
Merck Sharp & Dohme LLC
Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor, Neuroblastoma
12/10
12/10
NCT01048892: Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Completed
1
22
US
Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis, pharmacological study
Children's Oncology Group, National Cancer Institute (NCI)
Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma
06/13
 
NCT01477021: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Completed
1
6
US
cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, NY-ESO-1-specific T cells, laboratory biomarker analysis
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
09/13
 
NCT00662233: Combination Chemotherapy in Treating Patients With Sarcoma

Completed
1
28
US
cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, brachytherapy, intraoperative radiation therapy, radiation therapy
Mayo Clinic, National Cancer Institute (NCI)
Ovarian Cancer, Sarcoma
10/13
10/13
NCT01143545: Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Terminated
1
10
US
Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
National Cancer Institute (NCI)
Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
02/15
02/20
NCT01875601: NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Completed
1
16
US
Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion
National Cancer Institute (NCI)
Solid Tumors, Brain Tumors, Sarcoma, Pediatric Cancers, Neuroblastoma
09/15
09/15
NCT02059850: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Withdrawn
1
0
US
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
01/16
01/16
NCT01341496: Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

Terminated
1
41
US
Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
National Cancer Institute (NCI)
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
05/16
07/16
14-C-0059, NCT02107963: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Completed
1
15
US
Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
National Cancer Institute (NCI)
Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
08/16
01/17
METZOLIMOS, NCT02517918 / 2014-000196-85: Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma

Completed
1
23
Europe
Sirolimus combined with CP, MT and ZA, Endoxan, Methotrexate, Rapamune, Zoledronic acid
Institut Bergonié, Reliable Cancer Therapies, Pfizer
Solid Tumor, Osteosarcoma
09/16
11/21
Ewing/Allo, NCT02472392: Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed
1
10
US
Rabbit anti-thymocyte globulin, ATG, thymoglobulin, Busulfan, Busulfex, Myleran, Melphalan, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Neosar
University of Louisville
EWINGS SARCOMA
12/16
12/16
ADP 04511, NCT01343043 / 2015-005594-21: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Completed
1
50
US
NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide
GlaxoSmithKline
Neoplasms
06/19
06/19
AflacST1402, NCT02390843: Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

Completed
1
13
US
Simvastatin, zocor, Cyclophosphamide, Cytoxan, Neosar, Topotecan, Hycamtin, Myeloid growth factor, Granulocyte colony-stimulating factor (G-CSF), pegylated granulocyte colony-stimulating factor
Emory University, Children's Healthcare of Atlanta
Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
09/19
09/19
VEGAS, NCT01953900: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

Active, not recruiting
1
26
US
GD2 T cells, iC9-GD2-CAR-VZV-CTL, VZV vaccine, zostavax, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
Baylor College of Medicine, National Cancer Institute (NCI), Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Osteosarcoma, Neuroblastoma
10/19
10/34
NCT02457650: T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Unknown status
1
36
RoW
Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
Shenzhen Second People's Hospital, Shenzhen Institute for Innovation and Translational Medicine
Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Cancer, Synovial Sarcoma, Other Metastatic Solid Cancers
12/19
12/19
NCT02210104: Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Withdrawn
1
0
NA
Ipilimumab, Yervoy, BMS-734016, MDX010, Cyclophosphamide, Cytoxan, Neosar, CD4+ T cells
M.D. Anderson Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Melanoma, Sarcoma
12/19
 
NCT00902044: Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Active, not recruiting
1
36
US
Autologous HER2-specific T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Autologous CAR Positive T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, Cancer Prevention Research Institute of Texas
Sarcoma
12/19
07/32
NCT02502708: Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Checkmark From trial for front-line DIPG at ESMO-IO 2019
Dec 2019 - Dec 2019: From trial for front-line DIPG at ESMO-IO 2019
Checkmark Data in combination with radiation and chemotherapy for children with diffuse intrinsic pontine glioma at ISPNO
Jul 2018 - Jul 2018: Data in combination with radiation and chemotherapy for children with diffuse intrinsic pontine glioma at ISPNO
Checkmark In pediatric brain cancer at AACR 2018
More
Completed
1
81
US
Indoximod, 1-methyl-D-tryptophan, D-1MT, Temozolomide, Temodar, Methazolastone, Conformal Radiation, Cyclophosphamide, Etoposide
NewLink Genetics Corporation
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
12/19
02/20
NCT01313429: Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Terminated
1
19
US
Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib
National Cancer Institute (NCI)
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
02/20
02/20
NCT03399448: NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Terminated
1
3
US
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine, NY-ESO-1 expression testing
University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Tmunity Therapeutics
Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
02/20
10/20
NCT03960060: A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Active, not recruiting
1
18
RoW
CCT301-59
Shanghai PerHum Therapeutics Co., Ltd., Shanghai Zhongshan Hospital
Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer, Bladder Cancer
06/22
06/23
NCT05943990: Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Terminated
1
5
Europe, Canada, US, RoW
GSK3845097, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
10/22
10/22
NCT04661852: Cabozantinib With Topotecan-Cyclophosphamide

Completed
1
12
US
Cabozantinib, COMETRIQ™, Topotecan, Hycamtin®, Cyclophosphamide, Neosar®, Cytoxan®, Myeloid growth factor, Filgrastim, Pegfilgrastim
Dana-Farber Cancer Institute
Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
10/22
10/22
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Checkmark Initiation of pivotal monotherapy trial
Mar 2018 - Mar 2018: Initiation of pivotal monotherapy trial
Completed
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305
M.D. Anderson Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
12/22
12/22
NCT04052334: Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Completed
1
9
US
TIL, Tumor-infiltrating lymphocytes, Interleukin-2, IL-2, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Neosar
H. Lee Moffitt Cancer Center and Research Institute, Iovance Biotherapeutics, Inc., The V Foundation for Cancer Research, National Cancer Institute (NCI)
Sarcoma
05/23
05/24
NCT06048705: Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Terminated
1
7
Europe, Canada, US, RoW
GSK3901961, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
06/23
06/23
NCT02869217: Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Checkmark From P1 trial at ESMO 2019 [screenshot]
Sep 2019 - Sep 2019: From P1 trial at ESMO 2019 [screenshot]
Checkmark Data presentation from P1 trial in solid tumors
Jun 2019 - Jun 2019: Data presentation from P1 trial in solid tumors
Hourglass Nov 2016 - Mar 2017 : Initiation of trial in synovial sarcoma
Active, not recruiting
1
22
Canada
Cyclophosphamide, TBI-1301, Fludarabine
University Health Network, Toronto, Takara Bio Inc.
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma, Melanoma, Esophageal Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Liver Cancer
09/24
09/24
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
NCT05492682: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Recruiting
1
15
Europe
PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
Valo Therapeutics Oy
Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma, Myxoid Liposarcoma, Colorectal Cancer
06/25
09/25
NCT02013336: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Recruiting
1
30
US
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
South Plains Oncology Consortium
Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
12/23
12/23
NCT01661400: Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

Completed
1
14
US
Metronomic Cyclophosphamide, Cytoxan®, CPM, Thalidomide, Thalomid®
Washington University School of Medicine
Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Retinoblastoma
12/23
12/23
NCI-2019-01493, NCT03864419: Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated
1
18
RoW
Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Cyclophosphamide, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emthexat, Emtexate, Methotrexate LPF, Methylaminopterin, Methotrexatum, Doxorubicin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, Adriamycine, Adriblastina, Doxolem, Doxorubicin.HCl, Prednisone, Deltacortene, Decorton, Decortisyl, DeCortin, Deltacortisone, Econosone, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Vepesid, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar JHL1101, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, RTXM83, Truxima
Fred Hutchinson Cancer Center
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, Diffuse Large B-Cell Lymphoma
07/23
07/23
NCT03462316: NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Active, not recruiting
1
20
RoW
NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Bone Sarcoma, Soft Tissue Sarcoma
02/24
05/24
NCT04511871: A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Recruiting
1
15
RoW
CCT303-406
Shanghai PerHum Therapeutics Co., Ltd., Shanghai Zhongshan Hospital
Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer, Sarcoma
03/24
03/25
NCT06412458: IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Not yet recruiting
1
9
RoW
IM83 CAR-T Cells
Beijing Immunochina Medical Science & Technology Co., Ltd., Guangdong Provincial People's Hospital
Refractory Osteosarcoma, Recurrent Osteosarcoma
06/25
06/26
NCT03721068: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting
1
18
US
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
UNC Lineberger Comprehensive Cancer Center, United States Department of Defense, Bellicum Pharmaceuticals, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Neuroblastoma, Osteosarcoma
06/24
06/39
NCT05128786: CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

Recruiting
1
9
RoW
CCT301-38
Shanghai PerHum Therapeutics Co., Ltd., Shanghai Zhongshan Hospital
SAR
08/24
08/25
NCT04282044: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Recruiting
1
60
US
CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
BioEclipse Therapeutics
Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
08/25
10/26
NCT06474676: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Not yet recruiting
1
40
US
Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy, AttIL2-TIL
M.D. Anderson Cancer Center
Metastatic Soft-tissue Sarcoma
12/30
12/32
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Not yet recruiting
1
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25
NCT05103631: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Recruiting
1
27
US
CATCH T cells, GPC3-CAR T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
01/25
12/39
NCT04995003: HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Recruiting
1
25
US
T cells or CAR T cells, HER2 CAR T cells, Pembrolizumab Injectable Product, immune checkpoint inhibitor, Nivolumab Injectable Product
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Faris Foundation USA, Stand Up To Cancer, Triumph Over Kid Cancer Foundation, St. Baldrick's Foundation, National Cancer Institute (NCI)
Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma, Undifferentiated Sarcoma
12/27
12/40
H-47757 AGAR, NCT04377932: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Recruiting
1
24
US
AGAR T cells, GPC3-CAR T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine
Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
02/25
02/40
NCT05621668: A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Recruiting
1
40
US
Cyclophosphamide, Cytoxan®, Neosar®, attIL2-T cells
M.D. Anderson Cancer Center
Soft Tissue Sarcoma, Bone Sarcoma
09/25
09/25
NCT04897321: B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Recruiting
1
32
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, MESNA, Mesnex, B7-H3 CAR T cells, CAR T- cell infusion
St. Jude Children's Research Hospital
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
03/26
03/27
NCT04715191: Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Not yet recruiting
1
24
US
CARE T cells, 15.21.GPC3-CAR T cells, Cytoxan, Cyclophosphamide, Fludara, Fludarabine
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine
Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
08/26
07/41
NCT06083883: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Suspended
1
44
US
Fludarabine phosphate, Fludarabine, Fludara®, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
11/26
11/28
NCT05075993: Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Recruiting
1
352
US
LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
M.D. Anderson Cancer Center, Lyvgen Biopharma Holdings Limited
Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
02/27
02/27
NCT04539366: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Suspended
1
67
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Echocardiography, EC, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, GD2-CAR-expressing Autologous T-lymphocytes, tvs-CTL Vaccine, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Magnetic Resonance Imaging of the Heart, Cardiac MRI, Heart MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
12/40
12/40

Download Options